CL2020002371A1 - Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida - Google Patents

Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida

Info

Publication number
CL2020002371A1
CL2020002371A1 CL2020002371A CL2020002371A CL2020002371A1 CL 2020002371 A1 CL2020002371 A1 CL 2020002371A1 CL 2020002371 A CL2020002371 A CL 2020002371A CL 2020002371 A CL2020002371 A CL 2020002371A CL 2020002371 A1 CL2020002371 A1 CL 2020002371A1
Authority
CL
Chile
Prior art keywords
chloro
amino
fluorobenzamide
butanoyl
triazol
Prior art date
Application number
CL2020002371A
Other languages
English (en)
Inventor
Julian Egger
Daniel Götz
Michal Sowa
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of CL2020002371A1 publication Critical patent/CL2020002371A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un proceso para preparar 4-{[(2S)-2-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2- oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida (I) o 4-({(2S)-2-[4-{5-cloro-2-[4-(trifluorometil)-1H-1,2,3-triazol-1-il]fenil}-5- metoxi-2-oxopiridin-1(2H)-il]butanoil}amino)-2-fluorobenzamida (II) a partir de 2,5-dimetoxipiridina (III), 1-(2-bromo-4- clorofenil)-4-cloro-1H-1,2,3-triazol (X-Cl) o 1-(2-bromo-4-clorofenil)-4-(trifluorometil)-1H-1,2,3-triazol (X-CF3), 4-amino-2- fluorbenzamida (XIII) y ácido (2R)-2-aminobutanoico (XVII).
CL2020002371A 2018-03-15 2020-09-14 Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida CL2020002371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18161983 2018-03-15

Publications (1)

Publication Number Publication Date
CL2020002371A1 true CL2020002371A1 (es) 2021-01-29

Family

ID=61683650

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002371A CL2020002371A1 (es) 2018-03-15 2020-09-14 Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida

Country Status (29)

Country Link
US (1) US11542245B2 (es)
EP (2) EP3765452B1 (es)
JP (1) JP7287978B2 (es)
KR (1) KR102807521B1 (es)
CN (1) CN111770917B (es)
AR (1) AR117400A1 (es)
AU (1) AU2019236369B2 (es)
BR (1) BR112020018562A2 (es)
CA (1) CA3093733A1 (es)
CL (1) CL2020002371A1 (es)
DK (1) DK3765452T3 (es)
ES (1) ES2920449T3 (es)
HR (1) HRP20220565T1 (es)
HU (1) HUE058796T2 (es)
IL (2) IL277240B2 (es)
JO (1) JOP20200232B1 (es)
LT (1) LT3765452T (es)
MX (1) MX2020009580A (es)
MY (1) MY201167A (es)
PE (1) PE20211395A1 (es)
PL (1) PL3765452T3 (es)
PT (1) PT3765452T (es)
RS (1) RS63338B1 (es)
SG (1) SG11202006710RA (es)
SI (1) SI3765452T1 (es)
TW (1) TWI823911B (es)
UA (1) UA126940C2 (es)
UY (1) UY38147A (es)
WO (1) WO2019175043A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140558A (ko) * 2020-02-11 2022-10-18 케미노바 에이/에스 (r)-2-아미노부탄산으로부터 s-베플루부타미드를 합성하는 방법
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
JP2024508970A (ja) 2021-03-09 2024-02-28 バイエル・アクチエンゲゼルシヤフト （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含んでいる医薬剤形
MX2023010614A (es) * 2021-03-09 2023-09-19 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262724B (zh) * 2022-11-18 2025-04-29 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) * 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
KR20260021743A (ko) 2023-06-09 2026-02-13 청두 시베이캉 바이오메디칼 테크놀로지 컴퍼니 리미티드 옥소피리딘 화합물의 신규 제조방법, 핵심 중간체 및 그 용도
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020071931A (ko) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN107793396B (zh) 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
WO2020126682A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
PE20211790A1 (es) * 2018-12-21 2021-09-09 Bayer Ag Derivados de oxopiridina sustituidos
US20220144848A1 (en) * 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
EP3765452B1 (en) 2022-04-13
RS63338B1 (sr) 2022-07-29
CN111770917A (zh) 2020-10-13
SI3765452T1 (sl) 2022-06-30
TWI823911B (zh) 2023-12-01
EP3765452A1 (en) 2021-01-20
PL3765452T3 (pl) 2022-08-01
BR112020018562A2 (pt) 2020-12-29
EP3889147A1 (en) 2021-10-06
RU2020133706A (ru) 2022-04-18
US20210017152A1 (en) 2021-01-21
JOP20200232B1 (ar) 2023-09-17
MY201167A (en) 2024-02-08
PT3765452T (pt) 2022-06-23
CN111770917B (zh) 2023-09-26
HUE058796T2 (hu) 2022-09-28
JOP20200232A1 (ar) 2020-09-14
US11542245B2 (en) 2023-01-03
IL277240B2 (en) 2024-01-01
ES2920449T3 (es) 2022-08-04
LT3765452T (lt) 2022-05-25
AU2019236369A1 (en) 2020-07-30
UA126940C2 (uk) 2023-02-22
IL300463A (en) 2023-04-01
IL277240B1 (en) 2023-09-01
HRP20220565T1 (hr) 2022-06-10
CA3093733A1 (en) 2019-09-19
DK3765452T3 (da) 2022-06-27
PE20211395A1 (es) 2021-07-27
KR20200131241A (ko) 2020-11-23
KR102807521B1 (ko) 2025-05-16
SG11202006710RA (en) 2020-08-28
AU2019236369B2 (en) 2024-04-18
JP2021517573A (ja) 2021-07-26
MX2020009580A (es) 2020-10-05
WO2019175043A1 (en) 2019-09-19
TW202002969A (zh) 2020-01-16
IL277240A (en) 2020-10-29
JP7287978B2 (ja) 2023-06-06
AR117400A1 (es) 2021-08-04
UY38147A (es) 2019-10-01

Similar Documents

Publication Publication Date Title
CL2020002371A1 (es) Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida
FI2440547T3 (fi) Uusia silmukointimekanismia estäviä kemiallisia molekyylejä silmukointivirheistä johtuvien sairauksien hoitoon
CA2388320A1 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
NZ592802A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ609955A (en) Sgc stimulators
JP2016526561A5 (es)
NZ612544A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
JP2017524019A5 (es)
RU2017145929A (ru) МОДУЛЯТОРЫ ROR ГАММА(RORγ)
JOP20210227A1 (ar) شكل بلوري من مونوهيدرات 1-(1-أوكسو-1، 2-داي هيدروأيزوكينولين-5-يل)-5-(تراي فلوروميثيل)-n-(2-(تراي فلوروميثيل)بيريدين-4-يل)-1h-بيرازول-4-كربوكساميد
ES3059967T3 (en) Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
PH12019502830A1 (en) Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
RU2013110324A (ru) Новые модуляторы trpv3
TH2001005199A (th) กระบวนการเตรียมของสองอนุพันธ์ 4-{[(2s)-2-{4-[5-คลอโร-2-(1h-1,2,3-ไตรอะซอล-1-อิล) ฟีนิล)-5-เมทอกซี-2-ออกโซไพริดิน-1(2h)-อิล}บิวทาโนอิล]อะมิโน}-2-ฟลูออโรเบนซาไมด์
SG11202107438WA (en) Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
RU2010148901A (ru) Новые производные пиридина в качестве миметиков модуляторов лептинового рецептора
PL4126821T3 (pl) Sposób wytwarzania kwasu (r)-4-(1-(6-(4-(trifluoromety­lo)benzylo)-6-azaspiro[2.5]oktano-5-karboksyamido)cyklopropylo)benzoesowego lub jego soli
LT4178548T (lt) Farmacinė kompozicija, apimanti (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il) -1-oksoizoindolin-4-il)oksi)metil)benzil)piperazin-1-il)-3-fluorbenzonitrilą, ir jos panaudojimo būdai
RU2022129311A (ru) Способ получения двух 4-{ [(2s)-2-{ 4-[5-хлор-2-(1h-1,2,3-триазол-1-ил)фенил]-5-метокси-2-оксопиридин-1(2h)-ил} бутаноил]амино} -2-фторбензамидных производных
MX2025003814A (es) Sal farmacéuticamente aceptable y forma cristalina de un derivado de tetrahidronaftaleno y método de preparación
MX2023012911A (es) Metodos de tratamiento del mieloma multiple usando terapia combinada.
HK40064284A (en) Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same